课题基金 / 基金详情

Kupffer Cells in Liver Immunopathology

Kupffer Cells in Liver Immunopathology
肝脏免疫病理学中的库普弗细胞
批准号:
7251487
负责人:
Ian NICHOLAS Crispe
金额:
$37.87万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-01 至 2011-06-30
关键词:
AblationAcuteAdoptive TransferAffectAntibodiesAntigen TargetingAntigensAntiviral AgentsApoptosisApoptoticApplications GrantsBackBone Marrow TransplantationBystander EffectCD8B1 geneCell DeathCell Surface ReceptorsCell-Mediated CytolysisCellsCessation of lifeCharacteristicsChronicChronic Active HepatitisCytotoxic T-LymphocytesDependenceDependovirusDevelopmentDichloromethylene DiphosphonateDrug Delivery SystemsEffectivenessEncapsulatedEpitopesEventGenerationsGenotypeGreen Fluorescent ProteinsHepaticHepatitisHepatitis C virusHepatitis C-Like VirusesHepatocyteImmuneImmune responseImmunityImmunofluorescence ImmunologicImmunohistochemistryImpairmentIn Situ Nick-End LabelingInfectionInflammatory ResponseInfluenzaInjuryInjury to LiverInterferonsKupffer CellsLeadLightLiposomesLiverLymphocyte FunctionMacrophage Colony-Stimulating FactorMeasuresMediatingModelingMolecularMusNatureNumbersOVA-8OutcomeOvalbuminPathway interactionsPatientsPeptide FragmentsPeptide Nucleic AcidsPolymerase Chain ReactionPopulationPortal vein structurePrincipal InvestigatorProductionProteinsRNA InterferenceRecombinant adeno-associated virus (rAAV)RecombinantsRegulationRelative (related person)Research PersonnelRoleSatellite VirusesSignal PathwaySignal TransductionSiteStaining methodStainsT-Cell ReceptorT-LymphocyteTestingTherapeuticTimeTransgenic MiceTransgenic OrganismsTumor Necrosis Factor ReceptorViralViral hepatitisVirusVirus DiseasesWorkautocrinebasecytotoxicdesignfeedingimmunopathologyimprovedinfluenzavirusinhibitor/antagonistintrahepatickillingsliver allograftnanoparticlenovelpathogenprogramsreceptorresearch studyrespiratory virusresponsesmall moleculetherapeutic target

项目摘要

项目成果

Ian NICHOLAS Crispe的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The liver is unique in that it traps and kills activated CD8+ T cells. This results in the development of hepatitis, which is not driven by the direct recognition of antigen on hepatocytes by CD8+ T cells, but by an indirect or bystander mechanism. Our preliminary studies using a respiratory virus (influenza A) to drive the expansion and accumulation of antigen-specific CD8+ T cells in the liver indicate that this bystander hepatitis requires the presence of Kupffer cells (KCs). The significance of this work is twofold: First, we show that bystander hepatitis occurs in patients as well as mice infected with influenza and that hepatitis may be a general consequence of the hepatic clearance of large numbers of CD8+ T cells generated during the course of virus infections. Secondly, our analysis of bystander hepatitis has revealed the importance of KCs in mediating the deletion of intrahepatic CD8+ T cells as well as inducing the associated liver damage. We have recently developed a model of hepatotrophic viral infection using an Adeno-Associated Virus (AAV) encoding the SIINFEKL antigen recognized by CD8+ T cells from the OT-1 transgenic mouse. Using this AAV-OVA and an influenza model, we propose experiments to test the hypothesis that KC activation (mediated through interferon-g and TNFa) is critical for both the deletion of CD8+ T cells and the generation of hepatitis (Aim 1). Furthermore, we postulate that KC-mediated killing of anti-viral cytotoxic T lymphocytes (CTLs) inhibits the antiviral CTL response (Aim 2) and that KC-mediated bystander effect contributes to liver damage even in the context of an intrahepatic infection (Aim 3). Finally, we propose to test selective inhibition of KC activity as a novel therapy to improve viral clearance and decrease liver damage in our AAV- OVA model of hepatotrophic virus infection. These experiments will shed light on how KCs affect CTL-dependent immune responses in the liver and may clarify the mechanism through which hepatotrophic pathogens such as HCV evade immune clearance and establish chronic infections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Adaptive Liver Tolerance via LSECs
  • 批准号:
    10221498
  • 项目类别:
  • 资助金额:
    $38.88万
  • 财政年份:
    2018
  • 负责人:
    Ian NICHOLAS Crispe
  • 依托单位:
Adaptive Liver Tolerance via LSECs
  • 批准号:
    9788247
  • 项目类别:
  • 资助金额:
    $38.88万
  • 财政年份:
    2018
  • 负责人:
    Ian NICHOLAS Crispe
  • 依托单位:
Adaptive Liver Tolerance via LSECs
  • 批准号:
    10457946
  • 项目类别:
  • 资助金额:
    $38.88万
  • 财政年份:
    2018
  • 负责人:
    Ian NICHOLAS Crispe
  • 依托单位:
Help and suppression in liver tolerance
  • 批准号:
    9442460
  • 项目类别:
  • 资助金额:
    $30.17万
  • 财政年份:
    2017
  • 负责人:
    Ian NICHOLAS Crispe
  • 依托单位:
海外基金